Melbourne, Feb 11, 2009 (ABN Newswire) - Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that GlaxoSmithKline (LON:GSK) has advised of the current Relenza supply situation in respect to the key market of Japan.
Biota earns a 7% royalty on all global sales of Relenza by GSK.
The GlaxoSmithKline Release is below:
Additional Supply of anti-influenza virus drug Relenza for this flu season
GlaxoSmithKline K.K. (Head Office: Shibuya-ku, Tokyo, President: Marc Dunoyer, hereinafter referred to as GSK) has decided, based on this season's epidemic situation, to additionally import its anti-influenza virus drug Relenza (generic name: zanamivir hydrate) in order to maintain a stable supply.
2 million packs of Relenza are to be additionally imported. 0.4 million packs will be available in February, 0.6 million packs in March and 1 million packs in April.
GSK originally prepared for this flu season with 3 million packs of Relenza. This quantity is equivalent to meeting the requirement for half the prescriptions of anti-influenza virus drugs in an average year. However, due to reports that most of the prevailing A/H1N1 influenza virus, which accounts for about half of the current epidemic, are resistant to another antiinfluenza virus drug this year, attention and demand for Relenza has increased dramatically.
GSK believes that currently, there is enough Relenza in distribution in the market, but in order to prevent stock accumulation, GSK is controlling its shipment.
The additional importation of Relenza will enable GSK to maintain a stable supply. Although it is not possible to predict the size and duration of this season's flu epidemic, GSK will continue with our efforts to provide Relenza to all the patients who need it and promote its appropriate use.
Do more, feel better, live longer
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and health care companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Naomi Yoshida or Yoshiaki Komatsu
Tel: 03-5786-5041/5030
http://glaxosmithkline.co.jp
##ENDS##
Biota earns a 7% royalty on all global sales of Relenza by GSK.
The GlaxoSmithKline Release is below:
Additional Supply of anti-influenza virus drug Relenza for this flu season
GlaxoSmithKline K.K. (Head Office: Shibuya-ku, Tokyo, President: Marc Dunoyer, hereinafter referred to as GSK) has decided, based on this season's epidemic situation, to additionally import its anti-influenza virus drug Relenza (generic name: zanamivir hydrate) in order to maintain a stable supply.
2 million packs of Relenza are to be additionally imported. 0.4 million packs will be available in February, 0.6 million packs in March and 1 million packs in April.
GSK originally prepared for this flu season with 3 million packs of Relenza. This quantity is equivalent to meeting the requirement for half the prescriptions of anti-influenza virus drugs in an average year. However, due to reports that most of the prevailing A/H1N1 influenza virus, which accounts for about half of the current epidemic, are resistant to another antiinfluenza virus drug this year, attention and demand for Relenza has increased dramatically.
GSK believes that currently, there is enough Relenza in distribution in the market, but in order to prevent stock accumulation, GSK is controlling its shipment.
The additional importation of Relenza will enable GSK to maintain a stable supply. Although it is not possible to predict the size and duration of this season's flu epidemic, GSK will continue with our efforts to provide Relenza to all the patients who need it and promote its appropriate use.
Do more, feel better, live longer
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and health care companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Naomi Yoshida or Yoshiaki Komatsu
Tel: 03-5786-5041/5030
http://glaxosmithkline.co.jp
##ENDS##
| Tweet |
About Biota Holdings Limited
Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza.
Biota research breakthroughs have included a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease, licensed to AstraZeneca and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, Biota has a key partnership with Daiichi-Sankyo for the development of second generation influenza antivirals.
Relenza(TM) is a registered trademark of the GlaxoSmithKline group of companies. *Further information available at http://www.biota.com.au
|
||
|
 |
Related Companies |
>>>        Biota Holdings Limited>>> GlaxoSmithKline plc |
| |
Related Industry Topics: |
Biotech | Drugs & OTC | Health & Pharm General | |
| |
This Page Viewed: (Last 7 Days: 140) (Last 30 Days: 660) (Since Published: 34790) |
Events & Exhibitions
|
Site Search
| ENGLISH All Languages |
Upcoming WebCasts
 | Mr Mark Paton CEO Cue Energy Resources Tuesday, June 12, 2012 |
 | Mr Alan Hopkins CEO Pan Asia Corporation Tuesday, June 12, 2012 |
 | Mr Barry Dawes Martin Place Securities Tuesday, June 12, 2012 |
 | Dr Andrea Grant CEO Living Cell Technologies Monday, July 02, 2012 |
|
GlaxoSmithKline plc | ||||||
|
|||||||
Companies in the News
Mobile Video TV
|
||
|
||
